Buyback Yield

N/A

Dividend Yield

3.20%

Payout Ratio

270.8%

FCF Payout Ratio

65.1%

Revenue PS 5y CAGR

3.1%

Op. Income PS 5y CAGR

-5.5%

Operating Margin

16.2%

Updated a minute ago...

Price

136.7%

$ 214

$ 133

$ 51

2019

2021

2022

2023

2024

Mar 25

Revenue

$ 15 B

$ 7.56 B

$ 0

2019

2020

2021

2022

2023

Dec 24

Net Income

$ 4.49 B

$ 1.88 B

-$ 738 M

2019

2020

2021

2022

2023

Dec 24

Operating Income

$ 5.50 B

$ 2.01 B

-$ 1.49 B

2019

2020

2021

2022

2023

Dec 24

Free Cash Flow

$ 7.72 B

$ 3.86 B

$ 0

2019

2020

2021

2022

2023

Dec 24

Operating Cash Flow

$ 7.93 B

$ 3.97 B

$ 0

2019

2020

2021

2022

2023

Dec 24

Cost & OpEx

CapEx

$ 17 B

$ 8.44 B

$ 0

2019

2020

2021

2022

2023

Dec 24

Weighted Basic Shares

1.77 B

887 M

0

2019

2020

2021

2022

2023

Dec 24

Quarterly Dividends

3.20% Yield

$ 1.64

$ 0.82

$ 0

2020

2021

2022

2023

2024

Apr 25

Cash & Eqv.

Total Debt

$ 41 B

$ 23 B

$ 87 B

2019

2020

2021

2022

2023

Dec 24

Assets

Liabilities

No P/B

$ 151 B

$ 4.87 B

$ 141 B

2019

2020

2021

2022

2023

Dec 24

ROCE

17%

8.43%

0%

2020

2021

2022

2023

2024

Dec 24

P/OI Ratio

40

20

0

2020

2021

2022

2024

Today

Operating Income Margin

33%

16%

0%

2020

2021

2022

2023

2024

Dec 24

Operating Cash Flow Margin

46%

23%

0%

2020

2021

2022

2023

2024

Dec 24

AbbVie

AbbVie Inc.

Sector

🏥 Healthcare

Industry

Drug Manufacturers - General

Country

🇺🇸 United States

Employees

👥 50 000

Description
AbbVie discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

pet me to go up!

Thank you to catalyst for the lovely Profit Panda.

The stock data is sourced from Financial Modeling Prep.

If you have any questions or feedback, email me right away: hi@profitviz.com